Post-ACA Implementation Brings Opportunity And Uncertainty To Pharmaceutical Companies Looking To Capture Growth In New Places ACO and Exchange Information is the Most Critical to Understand in the next Six Months, According to Decision Resources Group
BURLINGTON, Mass., May 8, 2013 /PRNewswire/ -- Decision Resources Group, the premier provider of healthcare analysis and data globally, uses expert insight and proprietary data to anticipate and analyze implications of the coming paradigm shift in American healthcare. As ACOs continue to develop across the nation and states solidify their exchange plans for open enrollment, clarity on the true scope of market opportunity becomes critical for pharmaceutical companies.
"ACOs and Exchanges equate to a disruption of existing business models," explains Carolyn McMeekin, Vice President at HealthLeaders-InterStudy, a Decision Resources Group company. "As the healthcare industry moves away from fee-for-service, ACOs are the next step in the continued evolution of payment reform. And as the industry accepts and even embraces healthcare reform, Exchanges will be the foundation on which future insurance models are built."
The advent of ACO formation across the US has driven a need for insight beyond raw data to achieve understanding of true ROI in resource allocation. The true functional opportunity for pharmaceutical companies should be based on the specifics of the market compared to other markets—and each is different in its dynamics and key players' ability to manage risk, implement healthcare reform, and form ACOs.
State Exchanges have changed the way businesses look at account planning and strategy—and a clear view of the relative importance of the Exchanges has become crucial. More than just the decision to expand Medicaid, pharmaceutical companies should look at the individual and small-group market, the political affiliation of the governor and legislature…as well as profiling the largest and commercial and Medicaid MCOs.
In the great ocean of data, analysis and talking heads that surround every event of this magnitude, there is great power in simplicity—sifting through the noise takes time, and the essential things businesses need to know to make good decisions are best pulled out by experts. Decision Resources Group offers clarity. Visit SiftThroughTheNoise.com to find out more.
Introducing Two New Products!
About the NEW State Exchange Tracker: State-specific brand opportunity at a glance
State Exchange Tracker offers a concise, intuitive dashboard covering 26 states—and representing 74.3% of US population. This series combines analysis from several proprietary HealthLeaders-InterStudy databases and reports with expert insight. Find out more here.
About the NEW ACO Spotlight Series: Market-specific insight and implication dashboard
The ACO Spotlight Series provides clear, powerful profiles of the ACO landscape across 87 MSAs. This series leverages HealthLeaders-InterStudy's proprietary ACO database and experienced team of analysts to deliver concise, market-specific snapshots. Find out more here.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
SOURCE Decision Resources Group